The FDA declined to approve one of biotech's most closely watched cancer drugs
By Jaimy Lee
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer
The FDA declined to approve a new lung-cancer drug from Summit Therapeutics.
On Sunday, the Food and Drug Administration declined to approve a new lung-cancer drug, saying the biotech company developing the therapy needs to prove the drug can help people live longer.
In 2022, Summit Therapeutics licensed ivonescimab from Akeso, a Chinese biotech, paying up to $5 billion for the rights to the drug in the U.S., Canada, Europe and Japan.
Summit's stock (SMMT) plunged 10% in trading on Monday morning, while Hong Kong-listed shares of Akeso (HK:9926) were down 22.1%.
The company is trying to get the FDA to approve ivonescimab in combination with chemotherapy for certain patients with metastatic non-small-cell lung cancer. Ivonescimab targets two important proteins: PD-1 and VEGF. Drug developers believe that targeting both proteins will yield a better, potentially more durable response.
The Phase 3 trial, called HARMONi, found that the drug demonstrated an improvement in progression-free survival. But the FDA said it wants to see a statistically significant improvement in overall survival, not a "positive trend" toward overall survival or a post-hoc analysis.
"The HARMONi filing was always at risk: the study did not demonstrate a statistically significant overall survival benefit at its prespecified final analysis, despite FDA having guided this as necessary for approval," Leerink Partners analyst Daina Graybosch told investors. "We expect a modestly negative reaction in Summit."
Ivonescimab, which is already approved in China, is one of the most closely watched cancer drugs in development after a separate study showed the therapy produced better outcomes in lung-cancer patients when tested against Merck's Keytruda.
In the U.S., Summit has bet big on ivonescimab's potential. The company is testing the drug in several cancers, including colorectal cancer and renal cell carcinoma. It's also involved in numerous studies with other drugmakers testing ivonescimab alongside different cancer treatments. AstraZeneca (UK:AZN) recently made a $2 billion equity investment in Summit.
Summit's stock is down 19.2% so far this year, while the State Street SPDR S&P Biotech Exchange-Traded Fund XBI has gained 23.9%.
-Jaimy Lee
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-16-26 1007ET
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

Retirees: 5 Reasons to Consider Index Funds and ETFs

3 of the Best Core Stocks to Own

This Newly Undervalued Stock Has Plenty of Growth Ahead

4 Growth Stocks to Buy While They’re Still Undervalued

